TCRX
Tscan Therapeutics Inc
NASDAQ: TCRX · HEALTHCARE · BIOTECHNOLOGY
$1.15
-8.73% today
Updated 2026-04-29
Market cap
$75.73M
P/E ratio
—
P/S ratio
7.33x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Tscan Therapeutics Inc (TCRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-852.00%
ROE
-71.30%
ROA
-27.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $0.00 | $-13.66M | — | — | — |
| 2020 | $1.08M | $-26.13M | -1,796.50% | -2,417.79% | -2,408.02% |
| 2021 | $10.14M | $-48.63M | 100.00% | -479.65% | -479.49% |
| 2022 | $13.54M | $-66.22M | 100.00% | -492.32% | -489.26% |
| 2023 | $21.05M | $-89.22M | 100.00% | -444.00% | -423.86% |
| 2024 | $2.82M | $-127.50M | 100.00% | -4,787.68% | -4,527.66% |
| 2025 | $10.32M | $-129.77M | 72.24% | -1,315.38% | -1,256.81% |